Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from AuMake Ltd. ( (AU:XEN) ).
Xenitra reported a sharp rebound in its nutritionals business in the March quarter, with sales rising more than 300% to $8.3 million and cash receipts up over 200% versus the prior quarter, while corporate restructuring cut staff and administrative costs by 37% and 50% respectively. The company invested $8 million in inventory and initiated two higher-margin business units in OTC medicines and tokenised sales, ending the period with $1.83 million in cash and $2 million in receivables.
Operationally, Xenitra secured a one-year offtake agreement with key B2B customer Rockcheck Group for Danone products targeting about A$30 million in sales, with an option to extend for three more years and scope to add further product lines. It also acquired Hong Kong-based Fukang to underpin its cross-border OTC medicine business, gaining a pharmaceutical wholesale licence, online store assets and logistics services, with new product launches slated for the June quarter and the unit expected to scale by early FY27.
More about AuMake Ltd.
Xenitra Limited is an ASX-listed company operating in the nutritionals and over-the-counter medicines sectors, with a strong focus on supplying branded products into the China market. The business leverages Australian trading operations, e-commerce platforms and B2B partnerships to distribute nutrition and pharmaceutical products across Greater China.
Current Market Cap: A$11.59M
For a thorough assessment of XEN stock, go to TipRanks’ Stock Analysis page.